Trial Profile
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Malignant thymoma; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms CABINET
- 06 Feb 2024 According to an Exelixis media release, company is discussing these results with the U.S. Food and Drug Administration (FDA) to support a potential regulatory submission in 2024 and will provide an update when appropriate.
- 24 Oct 2023 Results (n=290, cut off between 10/2018-6/2023) presented at the 48th European Society for Medical Oncology Congress.
- 22 Oct 2023 Primary endpoint (Progression-free survival (PFS)) has been met, according to an Exelixis media release.